Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform
Executive Summary
Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.
You may also be interested in...
The Booming Business Of Drug Exclusions
The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.
Global COVID-19 Vaccine Spending Estimated At $157bn Through 2025 By IQVIA
Vaccine spending projections represent about 2% of total spending on medicines IQVIA said. Increased spending will be partly offset by COIVD-19 disruptions, however.
Raising Corporate Taxes Would Put US Investment At Risk, J&J CFO Warns
"I don't know why folks are anxious to have a race to the top in terms of rates," Joseph Wolk ways. After US tax reform in 2017, lowering the standard tax rate from 35% to 21%, J&J committed to increasing US investment 15% over the next four years.